GlaxoSmithKline faces inquiry over 'price fixing'
Fine could be as high as £2.6bn if competition rules were broken
The pharmaceuticals giant GlaxoSmithKline was yesterday accused of entering into agreements with rivals that may have prevented the NHS from being able to buy cheaper versions of one of its top-selling drugs.
The Office of Fair Trading alleged GSK abused its dominant market position, making payments to other companies that resulted in the delay of generic versions of the anti-depressant drug paroxetine, sold in the UK under the brand name Seroxat.
Because generic drugs are much cheaper than branded ones, the OFT claimed this meant the NHS may have been “denied significant cost savings”.
In a “statement of objections”, the watchdog alleged GSK struck deals with Alpharma, Generics and Norton Healthcare that “included substantial payments … in return for their commitment to delay their plans to supply paroxetine independently.”
Ann Pope, a senior director at the OFT, said: “The introduction of generic medicines can lead to strong competition on price, which can drive savings for the NHS, to the benefit of patients and, ultimately, taxpayers. It is therefore particularly important that the OFT fully investigates concerns that independent generic entry may have been delayed in this case.”
But she added: “No assumption can be made at this stage that there has been an infringement of competition law.”
The agreements being investigated were in place between 2001 and 2004. GSK denied the allegations, saying it “supports fair competition and we very strongly believe that we acted within the law, as the holder of valid patents for paroxetine, in entering the agreements under investigation.
“These arrangements resulted in other paroxetine products entering the market before GSK’s patents had expired.”
If GSK is found to have broken competition law, the company could be fined as much as 10 per cent of its worldwide turnover, which last year was £26.4bn.
Worldwide sales of Seroxat were £374m in 2012 – a 14 per cent drop on 2011 mainly due to “generic competition” according to GSK.
Diving in at the deep end is no excuse for shirking the style stakes
- 1 Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
- 2 Loom bands: Bids for dress made from colourful rubber pass £170,000 on eBay
- 3 Why I'm on the brink of burning my Israeli passport
- 4 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
- 5 The true Gaza back-story that the Israelis aren’t telling this week
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Loom bands: Bids for dress made from colourful rubber pass £170,000 on eBay
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Gaza-Israel conflict: The terrible price Palestinian children are paying for Israel’s war with Hamas
Iraq crisis: Government forces execute 255 Sunni prisoners in revenge for Isis atrocities, says report
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Australia facing international condemnation after turning around Sri Lankans at sea
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
iJobs Money & Business
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...
£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...